A Phase 4 interventional study of Haemoblock and Placebo in Vascular Diseases, Vascular Malformation and Capillary Malformation-Arteriovenous Malformation, sponsored by Center for Vascular Pathology, Moscow. Completed at 1 site in Russian Federation. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-04.
Sponsored by Center for Vascular Pathology, Moscow · Phase 4, Interventional, and Prevention
Among 12 studies in Vascular Diseases with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Vascular Diseases · Russian Federation.
Among the 12 studies in Vascular Diseases with a site in Russian Federation, this one is the 7th largest by enrollment of the 11 interventional ones, is one of 2 that started in 2020, is one of 2 in phase 4, and was the 12th registered.
694 studies on the registry are indexed under Vascular Diseases; 128 are open to participants now.
This study's enrollment of 200 is above the median of 96 across 419 interventional studies indexed under Vascular Diseases.
Browse Vascular Diseases studies →None of the 12 studies in Vascular Diseases with a site in Russian Federation is open now.
Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.
This study: 6 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2020.
Median enrollment 535 across the 11 interventional studies, 1,987 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
8 of 12 have an industry lead sponsor. The 9 most frequent:
Center for Vascular Pathology, Moscow is the lead sponsor of 3 studies on the registry; none are open to participants now.
Center for Vascular Pathology, Moscow has 1 study filed under Vascular Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Vascular Diseases with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Laser treatment (LT) is the first-line treatment for Vascular Pathology. However even when LT is based on the selective photothermolysis it causes the first-degree burns. While being typically benign by affecting only the epidermis, or outer layer of skin, the burn site is remaining red, dry, and very painful. As Haemoblock contains nanoparticles of silver and is known for both bactericidal and bacteriostatic effects, it likely decreases the potential for infection postoperatively. Furthermore, after fibrin replaces the superficial structure "Hemoblock-albumin", the polyacrylate matrix is plasmolyzed which initiates the cascade of signals required for the tissue regeneration processes. Objective of the study was to examine the effect of the Regenerative Solution "Hemoblock" in lowering postoperative complications in children diagnosed with Vascular Pathology undergoing a laser surgery if delivered with transdermal patches.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Haemoblock
Other: Placebo
Delivering with transdermal patches
Delivering with transdermal patches
Preventing negative outcomes of postoperative infection
Validated scales
Time frame: Early postoperative period and at 3 weeks
Preventing prolonged functional recovery
Validated scales
Time frame: Early postoperative period and at 3 weeks
Preventing likelihood of mental health issues
Validated scales
Time frame: Early postoperative period and at 3 weeks
Ran from Jan 2020 to primary completion in Aug 2021, 19 months.
Of 16 phase 4 interventional studies under Vascular Diseases, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 84. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Vascular Pathology, Moscow